Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
Status:
Recruiting
Trial end date:
2022-05-02
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin
compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb
ischemia undergoing infrapopliteal arterial endovascular intervention.